Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GLAXO ADDING TO CEPHALOSPORIN LINE WITH MOCHIDA LICENSING AGREEMENT

Executive Summary

GLAXO ADDING TO CEPHALOSPORIN LINE WITH MOCHIDA LICENSING AGREEMENT, which gives the U.K. firm exclusive rights to market the injectable antibiotic M-14659 outside of Japan. Under the agreement, announced Sept. 16, Glaxo will be responsible for development, manufacture, and marketing of the new antibiotic in all countries except Japan. Glaxo's Japanese subsidiary, Nippon Glaxo, will comarket the drug in Japan with Mochida, which will develop and manufacture the product in that country. Tokyo-based Mochida Pharmaceutical "will receive down payments and a running royalty as consideration for the license granted," Glaxo reported. Founded in 1945, Mochida has been synthesizing and investigating cephalosporin antibiotic derivatives since 1981. M-14659 is the first cephalosporin to be outlicensed by the Tokyo-based pharmaceutical company. M-14659 is still in the early stages of preclinical development. Glaxo indicated that the product would not be ready to enter human clinicals until 1988. However, Glaxo said that "early laboratory investigations on M-14659 have shown it to be a potent broad spectrum antibacterial agent active against both gram-negative and gram-positive organisms." Based on in Vitro studies, Glaxo said that the antibacterial's activity versus pseudomonas aeruginosa "appears to be stronger than any known antibiotic of its type." M-14659, Glaxo added, "is also effective against bacterial strains resistant to other cephalosporin antibiotics." Glaxo currently markets in the U.S. two third-generation injectable cephalosporins -- Fortaz (ceftazidime) and Zinacef (cefuroxime) -- and an injectable cephalothin under the Seffin brandname. In addition, Glaxo is expecting approval of its oral cefuroxime (Ceftin) in the near future. In an announcement of a comarketing agreement with Roche for the new oral cephalosporin, Glaxo predicted a 1987 approval. Glaxo is now running "available soon" ads in trade and professional journals.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

OM017175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel